We used the GLOW database to study the bone health management postmenopausal women with glucocorticoid exposure. GLOW is a 5-year observational study of 60,000 postmenopausal women enrolled in 17 sites in 10 countries in Europe, North America, and Australia. We studied the use of BMD testing within the past 3 years of the study and medical management in glucocorticoid-exposed individuals during the third year of survey in GLOW.
past 2 or more years at the 3-year survey and 29,080 (73 %) were nonusers. Our study demonstrated considerable differences in BMD management in glucocorticoid users by site and region (see Table 1 ). Glucocorticoidexposed individuals had greater use of BMD testing and medical management than nonusers, although the number of individuals remained low (≤51 %) worldwide in current continuous users. The proportion of individuals with current continuous use who were on calcium and vitamin D varied worldwide (35 to 80 and 32 to 89 %, respectively) as did AOM use (41 to 51 %). Among women who underwent BMD testing within the past 3 years, AOM and calcium/vitamin D use in glucocorticoid-exposed individuals was 1.8 times higher than that of nonusers (33 versus 18 %). Fifty percent of CC users were aware of an osteoporosis diagnosis while 29 % of nonusers were aware of an osteoporosis diagnosis.
Limitations include our inability to determine glucocorticoid dose or confirm duration of therapy. Limitations include the use of self-reported data that were not confirmed by chart review. Our sites may not be fully representative of a country or region.
We conclude that management of bone health for glucocorticoid-exposed individuals is not optimal worldwide.
